SCHEMBL3013146

SCHEMBL3013146

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(F)cc4F)CC3)n2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.47
MAPT P10636 5/20 0.43
USP2 O75604 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PKM P14618 2/20 0.43
ALDH1A1 P00352 5/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GBA1 P04062 1/20 0.41
NPC1 O15118 1/20 0.40
TNF P01375 1/20 0.40
NOD1 Q9Y239 1/20 0.40
AR P10275 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002804 0.92 MAPT (0.45) TSHRMAPTUSP2RECQLHSD17B10
SCHEMBL3010662 0.91 TSHR (0.44) TSHRMAPTUSP2RECQLHSD17B10
SCHEMBL3017998 0.90 TSHR (0.46) TSHRMAPTUSP2RECQLHSD17B10
SCHEMBL3007442 0.89 MAPT (0.49) TSHRMAPTUSP2RECQLHSD17B10
SCHEMBL3011204 0.88 MAPT (0.56) TSHRMAPTUSP2RECQLHSD17B10
SCHEMBL3008988 0.88 MAPT (0.49) TSHRMAPTUSP2RECQLHSD17B10
SCHEMBL3000211 0.87 ALDH1A1 (0.44) MAPTUSP2RECQLHSD17B10PKM
SCHEMBL3006960 0.87 MAPT (0.55) TSHRMAPTUSP2RECQLHSD17B10
SCHEMBL3008981 0.87 ALDH1A1 (0.47) TSHRMAPTUSP2RECQLHSD17B10
SCHEMBL3014062 0.86 ALDH1A1 (0.45) TSHRMAPTUSP2RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TSHR 3320/4885MAPT 18/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.